

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and the development of Chimeric Antigen Receptor T cell (CAR T) therapies for cancer, announced that 350 registered shares benefit from a double voting right as of May 25, 2022. As a result, the Company’s total number of voting rights is now 24,962,331.

This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.

Figures – Modified on 25 May 2022 following the Double Voting Rights:

Total amount of share capital (EUR)	78,584,224.33
Total Number of shares with single voting rights	20,225,581
Total Number of shares with double voting rights	2,368,375
Total Number of Shares	22,593,956
Total of voting rights	24,962,331
Total number of attributed warrants	1,997,190
Total number of shares with voting rights that could be created following the exercise of the attributed warrants	1,997,190
Total number of diluted shares (Outstanding shares + Warrants)	24,591,146
Total number of diluted shares with voting rights	26,959,521

Contact person for regulated information (financial, transparency)

By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com.

Further questions about the content of this release can be sent to investors@celyad.com.

About Celyad Oncology

Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.

Investor and Media Contacts:

Sara Zelkovic
Communications & Investor Relations Director
Celyad Oncology
investors@celyad.com